BioSpace News Archive

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B, and age-related diseases, announced that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.

Adial Pharmaceuticals, Inc. announced the publication of previously disclosed results from its Phase 3 ONWARD study in a peer-reviewed article in the European Journal of Internal Medicine.

Femasys, Inc., a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation certificate and CE Mark certification for four of its products.

Allogene Therapeutics Inc. announced the initiation of the pivotal Phase 2 ALPHA3 trial evaluating the use of cemacabtagene ansegedleucel as part of the first line treatment regimen for newly diagnosed LBCL patients who are likely to relapse after standard 1L treatment and need further therapy.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.

GT Medical Technologies, Inc. today announced two significant additions to its leadership team: Tom Moore as Chief Commercial Officer and Sandeep Yadav as Chief Financial Officer.

Aranscia, a leading provider of personalized diagnostic solutions, and Signature RX, a leading pharmacy supplier and 503B manufacturer, announced a partnership to develop novel biomarkers and a personalized medication management solution for the effective use of GLP-1 medications.

Gilead Sciences, Inc. announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.

Scilex Holding Company announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC.

10x Genomics, Inc., a leader in single cell and spatial biology, announced that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel.